secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001193125-25-230409
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing
------------------------------------------------------------------------------

- OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.
- No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.
- PIPE financing of up to $175.1M (initial $80.8M) from sale of Series B Preferred and warrants at $1.40/share.
- Warrants exercisable after stockholder approval; proceeds for R&D and working capital; closing Oct 6, 2025.
- KCC2 program updates: OV350 topline PK data Q4 2025; OV4071 IND filing Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer